Stock Events

Stock Events

Immuron Limited 

$0.8312
26
-$0.02-2.21%Friday 20:59
+$0.00+0%Friday 21:00After hours

Statistics

Day High
0.8186
Day Low
0.8186
52W High
1.99
52W Low
0.677
Volume
140
Avg. Volume
-
Mkt Cap
6.71M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 28Expected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.01
-0
-0
0
Expected EPS
-0.00008854912
Actual EPS
N/A

Financials

-47.74%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.23MRevenue
-2.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRN. It's not an investment recommendation.
Eos Energy Enterprises
5
EOSE
Rocket Lab
4
RKLB
IonQ
4
IONQ
NVIDIA
3
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics works on therapies for autoimmune diseases, which overlaps with Immuron's work on immune modulation.
Rigel Pharmaceuticals
RIGL
Mkt Cap958.46M
Rigel Pharmaceuticals focuses on discovering and developing novel small-molecule drugs for immune disorders, directly competing with Immuron's product portfolio.
Adma Biologics
ADMA
Mkt Cap2.56B
ADMA Biologics specializes in immune globulin products, which are in the same therapeutic area as Immuron's immunotherapy products.
AIM ImmunoTech
AIM
Mkt Cap6.16M
AIM ImmunoTech works on therapies for diseases of immune dysregulation, aligning closely with Immuron's focus on immune system modulation.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics is involved in developing treatments for autoimmune diseases, which competes with Immuron's focus on immune system health.
Cytodyn
CYDY
Mkt Cap315.04M
CytoDyn is focused on developing innovative treatments for autoimmune and inflammatory diseases, directly competing with Immuron's therapeutic focus.
Protalix BioTherapeutics
PLX
Mkt Cap208.68M
Protalix BioTherapeutics engages in developing treatments for disorders caused by enzyme deficiencies, which indirectly competes with Immuron's work on immune-related diseases.

About

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.
Show More
CEO
Steven George Lydeamore
Employees
8
Country
Australia
ISIN
US45254U1016
WKN
000A2DTD8

Listings

STU
DE
ANWA.STU
STU
DE
ANW.STU
MU
DE
ANWA.MU
MU
DE
ANW.MU

0 Comments

Share your thoughts

FAQs

What is Immuron Limited stock price today?▼
The current price of IMRN is $0.83 USD — it has decreased by -2.21% in the past 24 hours. Watch Immuron Limited stock price performance more closely on the chart.
What is Immuron Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immuron Limited stocks are traded under the ticker IMRN.
Is Immuron Limited stock price growing?▼
IMRN stock has fallen by -5.55% compared to the previous week, the month change is a -23.74% fall, over the last year Immuron Limited has showed a -49.32% decrease.
What is Immuron Limited market cap?▼
Today Immuron Limited has the market capitalization of 6.71M
When is the next Immuron Limited earnings date?▼
Immuron Limited is going to release the next earnings report on February 19, 2027.
What is Immuron Limited revenue for the last year?▼
Immuron Limited revenue for the last year amounts to 5.23M USD.
What is Immuron Limited net income for the last year?▼
IMRN net income for the last year is -2.5M USD.
How many employees does Immuron Limited have?▼
As of November 7, 2026, the company has 8 employees.
In which sector is Immuron Limited located?▼
Immuron Limited operates in the Health & Wellness sector.
When did Immuron Limited complete a stock split?▼
The last stock split for Immuron Limited was on November 17, 2014 with a ratio of 1:40.
Where is Immuron Limited headquartered?▼
Immuron Limited is headquartered in Carlton, Australia.